Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
Conditions: Tuberculosis; Tuberculosis, Pulmonary; Bacterial Infections Respiratory; Lung Diseases; Mycobacterium Infections Intervention: Drug: 500mg BTZ-043 containing 3.7 MBq of [14C]BTZ-043 Sponsors: Michael Hoelscher; Leibniz Institute for Natural Product Research and Infection Biology Hans Knöll Institut Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials